| 000 | 01811 a2200469 4500 | ||
|---|---|---|---|
| 005 | 20250515230047.0 | ||
| 264 | 0 | _c20101203 | |
| 008 | 201012s 0 0 eng d | ||
| 022 | _a1569-8041 | ||
| 024 | 7 |
_a10.1093/annonc/mdq182 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aZucca, E | |
| 245 | 0 | 0 |
_aGastric marginal zone lymphoma of MALT type: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. _h[electronic resource] |
| 260 |
_bAnnals of oncology : official journal of the European Society for Medical Oncology _cMay 2010 |
||
| 300 |
_av175-6 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Practice Guideline; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 |
_aAnti-Bacterial Agents _xtherapeutic use |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal _xtherapeutic use |
| 650 | 0 | 4 |
_aBiomarkers _xmetabolism |
| 650 | 0 | 4 | _aBiopsy |
| 650 | 0 | 4 | _aBreath Tests |
| 650 | 0 | 4 | _aEndoscopy |
| 650 | 0 | 4 |
_aEurope _xepidemiology |
| 650 | 0 | 4 |
_aFeces _xchemistry |
| 650 | 0 | 4 | _aFollow-Up Studies |
| 650 | 0 | 4 |
_aHelicobacter Infections _xcomplications |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aIncidence |
| 650 | 0 | 4 |
_aL-Lactate Dehydrogenase _xanalysis |
| 650 | 0 | 4 |
_aLymphoma, B-Cell _xchemistry |
| 650 | 0 | 4 |
_aLymphoma, B-Cell, Marginal Zone _xdiagnosis |
| 650 | 0 | 4 | _aNeoplasm Staging |
| 650 | 0 | 4 | _aRandomized Controlled Trials as Topic |
| 650 | 0 | 4 | _aRisk Assessment |
| 650 | 0 | 4 | _aSecondary Prevention |
| 650 | 0 | 4 |
_aStomach Neoplasms _xdiagnosis |
| 650 | 0 | 4 |
_aUrea _xanalysis |
| 650 | 0 | 4 |
_abeta 2-Microglobulin _xanalysis |
| 700 | 1 | _aDreyling, M | |
| 773 | 0 |
_tAnnals of oncology : official journal of the European Society for Medical Oncology _gvol. 21 Suppl 5 _gp. v175-6 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1093/annonc/mdq182 _zAvailable from publisher's website |
| 999 |
_c19904168 _d19904168 |
||